Novo Nordisk salvaged a scrapped Parkinson’s cell therapy project by partnering with an AI biotech.
The Story
This deal demonstrates AI's role in rescuing failed R&D initiatives and finding new pathways for complex therapies.
Why It Matters
This isn't just about a big name like Novo. It shows AI moving past hype to deliver real results in drug discovery. For a small biotech or CRO, this means rethinking how you manage project risk and R&D pipelines. The ability to find value in stalled or failed projects through AI offers a clear strategic advantage, especially with the EU AI Act approaching.
What To Do About It
Review your own shelved projects and consider what data exists. Could a targeted AI analysis, even with tools like Copilot Studio, identify new angles or patient cohorts? I help firms like yours audit legacy data and identify low-risk, high-impact AI opportunities for compliance and competitive edge.
